Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party E-Reference-Cited by-同舟云学术

Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party E

Published:2018-08-15 Issue:9 Volume:93 Page:1142-1152
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Gilleece Maria H.¹^ORCID,Labopin Myriam²,Yakoub-Agha Ibrahim³,Volin Liisa⁴,Socié Gerard⁵,Ljungman Per⁶,Huynh Anne⁷,Deconinck Eric⁸,Wu Depei⁹,Bourhis Jean Henri¹⁰,Cahn Jean Yves¹¹,Polge Emmanuelle¹²,Mohty Mohamad¹³,Savani Bipin N.¹⁴,Nagler Arnon¹⁵

Affiliation:

1. Department of Haematology; Leeds Teaching Hospitals Trust, University of Leeds; Leeds United Kingdom

2. EBMT Paris Study Office/CEREST-TC; Paris France

3. CHU de Lille, LIRIC, INSERM U995; Université de Lille; Lille France

4. Comprehensive Cancer Center, Stem Cell Transplantation Unit; Helsinki University Hospital; Helsinki Finland

5. Service d'Hématologie Greffe; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris; Paris France

6. Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital; Stockholm Sweden

7. Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole; Toulouse France

8. Hematology Department; CHRU Besancon, INSERM UMR1098, Universite de Franche-Comte; Besancon France

9. Department of Hematology; First Affiliated Hospital of Soochow University; Suzhou Jiangsu China

10. Department of Haematology; Institute Gustave Roussy; Paris France

11. Department of Haematology, Centre Hospital; Universitaire Grenoble Alpes; Grenoble France

12. Acute Leukemia Working Party; European Society for Blood and Marrow Transplantation Paris Study Office/European Center for Biostatistical and Epidemiological Evaluation in Hematopoietic Cell Therapy (CEREST-TC); Paris France

13. Hopital Saint-Antoine, Université Pierre and Marie Curie, Institut National de la Santé et de la Recherche Médicale Unite Mixte de Recherche U938; Paris France

14. Division of Hematology/Oncology, Department of Internal Medicine; Vanderbilt University Medical Center; Nashville Tennessee

15. Chaim Sheba Medical Center; Tel Aviv University; Tel-Hashomer Israel

Funder

The study was supported by the European Blood & Marrow Transplantation funded by annual subscription from the constituent transplant centers.

European Blood & Marrow Transplantation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25211/fullpdf

Reference97 articles.

1. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?;Cornelissen;Blood,2007

2. Reduced mortality after allogeneic hematopoietic-cell transplantation;Gooley;N Engl J Med,2010

3. The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach;Cornelissen;Nat Rev Clin Oncol,2012

4. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study;Terwijn;J Clin Oncol Off J Am Soc Clin Oncol,2013

5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2016

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Cell Transplantation in Adult With Acute Myeloid Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice;Hematology;2023-12-08

3. Optimal Post-Remission Consolidation Therapy in Patients with AML;Acta Haematologica;2023-11-26

4. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms;Annals of Hematology;2023-10-25

5. Donor lymphocyte infusion in Acute Myeloid Leukemia;Best Practice & Research Clinical Haematology;2023-09